Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2002 May;39(5):315–322. doi: 10.1136/jmg.39.5.315

Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas

A Mohyuddin 1, W Neary 1, A Wallace 1, C Wu 1, S Purcell 1, H Reid 1, R Ramsden 1, A Read 1, G Black 1, D Evans 1
PMCID: PMC1735110  PMID: 12011146

Abstract

Neurofibromatosis type 2 (NF2) must be suspected in patients presenting with a unilateral vestibular schwannoma at a young age who are therefore at theoretical risk of developing bilateral disease. We identified 45 patients aged 30 years or less at the onset of symptoms of a unilateral vestibular schwannoma. Molecular genetic analysis of the NF2 gene was completed on peripheral blood samples in all 45 and on 28 tumour samples. No pathogenic NF2 mutations were identified in any of the blood samples. NF2 point mutations were identified in 21/28 (75%) tumour samples and loss of heterozygosity (LOH) in 21/28 (75%) tumour samples. Both mutational hits were identified in 18/28 (65%) tumour samples. In one multilobular tumour, one (presumably first hit) mutation was confirmed which was common to different foci of the tumour, while the second mutational event differed between foci. The molecular findings in this patient were consistent with somatic mosaicism for NF2 and the clinical diagnosis was confirmed with the presence of two meningiomas on a follow up MRI scan. A further patient developed a contralateral vestibular schwannoma on a follow up MRI scan in whom neither of the truncating mutations in the vestibular schwannoma were present in blood.

It is important when counselling patients with unilateral vestibular schwannomas to identify (1) those at risk of bilateral disease, (2) those at risk of developing other tumours, and (3) other family members at risk of developing NF2. Comparing tumour and blood DNA cannot exclude mosaicism in the index case and cannot, therefore, be used to predict those at risk of developing further tumours. However, identification of both mutations or one mutation plus LOH in the tumour and exclusion of those mutations in the blood samples of the sibs or offspring of the affected case may be sufficient to render further screening unnecessary in these relatives.

Full Text

The Full Text of this article is available as a PDF (192.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bourn D., Carter S. A., Mason S., Gareth D., Evans R., Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet. 1994 May;3(5):813–816. doi: 10.1093/hmg/3.5.813. [DOI] [PubMed] [Google Scholar]
  2. Bourn D., Strachan T. Highly polymorphic dinucleotide repeat at the NF2 gene. Hum Genet. 1995 Jun;95(6):712–712. doi: 10.1007/BF00209494. [DOI] [PubMed] [Google Scholar]
  3. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  4. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans D. G., Lye R., Neary W., Black G., Strachan T., Wallace A., Ramsden R. T. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):764–767. doi: 10.1136/jnnp.66.6.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans D. G., Ramsden R., Huson S. M., Harris R., Lye R., King T. T. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993 May;107(5):401–406. doi: 10.1017/s002221510012328x. [DOI] [PubMed] [Google Scholar]
  7. Evans D. G., Wallace A. J., Wu C. L., Trueman L., Ramsden R. T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. doi: 10.1086/512074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gyapay G., Morissette J., Vignal A., Dib C., Fizames C., Millasseau P., Marc S., Bernardi G., Lathrop M., Weissenbach J. The 1993-94 Généthon human genetic linkage map. Nat Genet. 1994 Jun;7(2 Spec No):246–339. doi: 10.1038/ng0694supp-246. [DOI] [PubMed] [Google Scholar]
  9. Jacoby L. B., MacCollin M., Louis D. N., Mohney T., Rubio M. P., Pulaski K., Trofatter J. A., Kley N., Seizinger B., Ramesh V. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994 Mar;3(3):413–419. doi: 10.1093/hmg/3.3.413. [DOI] [PubMed] [Google Scholar]
  10. Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Fünsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. doi: 10.1007/s004390050255. [DOI] [PubMed] [Google Scholar]
  11. Kluwe L., Mautner V. F. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998 Dec;7(13):2051–2055. doi: 10.1093/hmg/7.13.2051. [DOI] [PubMed] [Google Scholar]
  12. MacCollin M., Ramesh V., Jacoby L. B., Louis D. N., Rubio M. P., Pulaski K., Trofatter J. A., Short M. P., Bove C., Eldridge R. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994 Aug;55(2):314–320. [PMC free article] [PubMed] [Google Scholar]
  13. Marineau C., Baron C., Delattre O., Zucman J., Thomas G., Rouleau G. A. Dinucleotide repeat polymorphism at the D22S268 locus. Hum Mol Genet. 1993 Mar;2(3):336–336. doi: 10.1093/hmg/2.3.336-a. [DOI] [PubMed] [Google Scholar]
  14. Martuza R. L., Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988 Mar 17;318(11):684–688. doi: 10.1056/NEJM198803173181106. [DOI] [PubMed] [Google Scholar]
  15. Martuza R. L., Ojemann R. G. Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery. 1982 Jan;10(1):1–12. [PubMed] [Google Scholar]
  16. Mérel P., Hoang-Xuan K., Sanson M., Bijlsma E., Rouleau G., Laurent-Puig P., Pulst S., Baser M., Lenoir G., Sterkers J. M. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. doi: 10.1002/gcc.2870120206. [DOI] [PubMed] [Google Scholar]
  17. Neary W. J., Newton V. E., Laoide-Kemp S. N., Ramsden R. T., Griffith G., Evans D. G., Harris R., Strachan T. A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. J Laryngol Otol. 1996 Jul;110(7):634–640. [PubMed] [Google Scholar]
  18. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  19. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  20. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  21. Rouleau G. A., Wertelecki W., Haines J. L., Hobbs W. J., Trofatter J. A., Seizinger B. R., Martuza R. L., Superneau D. W., Conneally P. M., Gusella J. F. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. doi: 10.1038/329246a0. [DOI] [PubMed] [Google Scholar]
  22. Saeed S. R., Woolford T. J., Ramsden R. T., Lye R. H. Magnetic resonance imaging: a cost-effective first line investigation in the detection of vestibular schwannomas. Br J Neurosurg. 1995;9(4):497–503. doi: 10.1080/02688699550041133. [DOI] [PubMed] [Google Scholar]
  23. Schuler G. D., Boguski M. S., Stewart E. A., Stein L. D., Gyapay G., Rice K., White R. E., Rodriguez-Tomé P., Aggarwal A., Bajorek E. A gene map of the human genome. Science. 1996 Oct 25;274(5287):540–546. [PubMed] [Google Scholar]
  24. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  25. Weissenbach J., Gyapay G., Dib C., Vignal A., Morissette J., Millasseau P., Vaysseix G., Lathrop M. A second-generation linkage map of the human genome. Nature. 1992 Oct 29;359(6398):794–801. doi: 10.1038/359794a0. [DOI] [PubMed] [Google Scholar]
  26. Wu C. L., Thakker N., Neary W., Black G., Lye R., Ramsden R. T., Read A. P., Evans D. G. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet. 1998 Dec;35(12):973–977. doi: 10.1136/jmg.35.12.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zucman-Rossi J., Legoix P., Der Sarkissian H., Cheret G., Sor F., Bernardi A., Cazes L., Giraud S., Ollagnon E., Lenoir G. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet. 1998 Dec;7(13):2095–2101. doi: 10.1093/hmg/7.13.2095. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES